Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)

NCT00093015 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4038

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Disease
Diabetes Mellitus
Anemia

Interventions

DRUG: Placebo
DRUG: darbepoetin alfa

Sponsor

Amgen